ArticleThe American journal of pathology2007
The cartilage matrix protein subdomain of type VII collagen is pathogenic for epidermolysis bullosa acquisita.
Article in The American journal of pathology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 63 citations in OpenAlex.
- Autoimmune bullous diseases: pathogenesis and clinical management.Molecular biomedicine · 2025Review
- Pemphigoid disease model systems for clinical translation.Frontiers in immunology · 2025Review
- Epidermolysis Bullosa Acquisita: The 2019 Update.Frontiers in medicine · 2018Review
- Autoantibodies to Multiple Epitopes on the Non-Collagenous-1 Domain of Type VII Collagen Induce Blisters.The Journal of investigative dermatology · 2015Article
- Blister-inducing antibodies target multiple epitopes on collagen VII in mice.Journal of cellular and molecular medicine · 2014Article
- Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita.ISRN dermatology · 2013Article
- Article
- Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen.Autoimmunity · 2012Review
- Epidermolysis bullosa acquisita with moderately severe Dysphagia due to esophageal strictures.Indian journal of dermatology · 2011Article
- Immune reactivity to type VII collagen: implications for gene therapy of recessive dystrophic epidermolysis bullosa.Gene therapy · 2010Article
- Cross-reactivity of autoantibodies from patients with epidermolysis bullosa acquisita with murine collagen VII.Cellular and molecular life sciences : CMLS · 2010Article
- Reduction of collagen VII anchoring fibrils in the airway basement membrane zone of infant rhesus monkeys exposed to house dust mite.American journal of physiology. Lung cellular and molecular physiology · 2010Article
- Extracellular matrix molecules: potential targets in pharmacotherapy.Pharmacological reviews · 2009Review
- Ocular Manifestations and Management of Autoimmune Bullous Diseases.Journal of ophthalmic & vision researchReview
- Epidermolysis bullosa acquisita.Clinics in dermatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Epidermolysis bullosa acquisita (EBA) is an acquired bullous disease of the skin characterized by IgG autoantibodies against type VII (anchoring fibril) collagen. We previously defined four immunodominant antigenic epitopes within the noncollagenous 1 (NC1) domain of type VII collagen. In this study, we produced an additional recombinant fusion protein from the NC1 domain corresponding to the N-terminal 227 amino acids (residues 1 to 227), which contains homology with cartilage matrix protein (CMP). Using enzyme-linked immunosorbent assay and immunoblot analysis, we tested sera from EBA patients (n = 32), bullous systemic lupus erythematosus patients (n = 3), bullous pemphigoid patients (n = 15), and normal humans (n = 12). Twenty-six of 32 EBA sera and two of three bullous systemic lupus erythematosus sera reacted with the CMP domain, whereas none of the control sera did. Affinity-purified anti-CMP EBA antibodies injected into hairless mice produced the clinical, histological, immunological, and ultrastructural features of EBA. F(ab')(2) fragments generated from anti-CMP EBA autoantibodies did not induce disease. Our studies provide the first evidence that EBA autoantibodies to the CMP subdomain of NC1 are pathogenic and induce blister formation. This is the first antigenic epitope on type VII collagen demonstrated to be a pathogenic target for EBA autoantibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.